Stereotaxis (STXS): Price and Financial Metrics


Stereotaxis (STXS): $2.18

-0.05 (-2.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

STXS POWR Grades

  • STXS scores best on the Stability dimension, with a Stability rank ahead of 53.86% of US stocks.
  • The strongest trend for STXS is in Growth, which has been heading up over the past 177 days.
  • STXS's current lowest rank is in the Quality metric (where it is better than 23.06% of US stocks).

STXS Stock Summary

  • For STXS, its debt to operating expenses ratio is greater than that reported by only 19.02% of US equities we're observing.
  • In terms of twelve month growth in earnings before interest and taxes, STEREOTAXIS INC is reporting a growth rate of 108.74%; that's higher than 86.82% of US stocks.
  • Revenue growth over the past 12 months for STEREOTAXIS INC comes in at -13.45%, a number that bests merely 11.45% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to STEREOTAXIS INC are ZUO, RSKD, INTA, LUCD, and PD.
  • STXS's SEC filings can be seen here. And to visit STEREOTAXIS INC's official web site, go to www.stereotaxis.com.

STXS Valuation Summary

  • In comparison to the median Healthcare stock, STXS's price/sales ratio is 18% higher, now standing at 5.9.
  • Over the past 223 months, STXS's price/sales ratio has gone down 12.7.

Below are key valuation metrics over time for STXS.

Stock Date P/S P/B P/E EV/EBIT
STXS 2022-12-02 5.9 6.2 -9.1 -8.2
STXS 2022-12-01 6.1 6.4 -9.4 -8.5
STXS 2022-11-30 6.1 6.4 -9.5 -8.6
STXS 2022-11-29 6.1 6.4 -9.4 -8.5
STXS 2022-11-28 5.7 6.0 -8.8 -7.9
STXS 2022-11-25 5.8 6.0 -8.9 -8.0

STXS Growth Metrics

    Its year over year revenue growth rate is now at 13.35%.
  • The 3 year net income to common stockholders growth rate now stands at -199.73%.
  • The 4 year net cashflow from operations growth rate now stands at 23.73%.
STXS's revenue has moved down $3,077,686 over the prior 70 months.

The table below shows STXS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 29.08643 -7.918919 -18.83483
2022-06-30 30.53588 -6.005304 -18.53611
2022-03-31 33.4353 -4.833745 -14.61271
2021-12-31 35.02086 -2.945911 -12.06065
2021-09-30 33.60519 -0.582029 -9.889141
2021-06-30 33.20232 -0.445619 -6.847937

STXS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • STXS has a Quality Grade of B, ranking ahead of 89.02% of graded US stocks.
  • STXS's asset turnover comes in at 0.581 -- ranking 75th of 186 Medical Equipment stocks.
  • FONR, SMLR, and KIDS are the stocks whose asset turnover ratios are most correlated with STXS.

The table below shows STXS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.581 0.676 -2.014
2021-03-31 0.516 0.684 -1.715
2020-12-31 0.504 0.712 -1.512
2020-09-30 0.536 0.708 -1.279
2020-06-30 0.565 0.786 -0.976
2020-03-31 0.739 0.795 -0.864

STXS Stock Price Chart Interactive Chart >

Price chart for STXS

STXS Price/Volume Stats

Current price $2.18 52-week high $7.22
Prev. close $2.23 52-week low $1.55
Day low $2.13 Volume 197,800
Day high $2.24 Avg. volume 314,017
50-day MA $1.91 Dividend yield N/A
200-day MA $2.41 Market Cap 163.04M

Stereotaxis (STXS) Company Bio


Stereotaxis Inc. designs, manufactures, and markets advanced cardiology instrument control system for use in the cath lab that is used in the treatment of coronary artery disease and arrhythmias. The Company markets Stereotaxis System in the United States and Europe.


STXS Latest News Stream


Event/Time News Detail
Loading, please wait...

STXS Latest Social Stream


Loading social stream, please wait...

View Full STXS Social Stream

Latest STXS News From Around the Web

Below are the latest news stories about STEREOTAXIS INC that investors may wish to consider to help them evaluate STXS as an investment opportunity.

Stereotaxis to Participate in Piper Sandler 34th Annual Healthcare Conference

ST. LOUIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 34th Annual Healthcare Conference. Mr. Fischel will present on Stereotaxis’ business and technology during a Fireside Discussion on Thursday, December 1, 2022, at 9:00 am ET. He will then join a panel discussion on “The Future of Robotic

Yahoo | November 28, 2022

Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Stereotaxis Reports 2022 Third Quarter Financial Results

ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022. “Stereotaxis continues to demonstrate robust commercial and technological progress,” said David Fischel, Chairman and CEO. “We received two system orders in the third quarter, and have already received two additional signed purchase contracts as we

Yahoo | November 10, 2022

Delcath Systems, Inc. (DCTH) Reports Q3 Loss, Tops Revenue Estimates

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 12.38% and 10.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022

Thermo Fisher Scientific (TMO) Beats Q3 Earnings and Revenue Estimates

Thermo Fisher (TMO) delivered earnings and revenue surprises of 6.28% and 8.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | October 26, 2022

Read More 'STXS' Stories Here

STXS Price Returns

1-mo 19.78%
3-mo 11.79%
6-mo 1.40%
1-year -63.91%
3-year -51.23%
5-year 172.50%
YTD -64.84%
2021 21.81%
2020 -3.78%
2019 389.36%
2018 35.13%
2017 23.10%

Continue Researching STXS

Want to see what other sources are saying about Stereotaxis Inc's financials and stock price? Try the links below:

Stereotaxis Inc (STXS) Stock Price | Nasdaq
Stereotaxis Inc (STXS) Stock Quote, History and News - Yahoo Finance
Stereotaxis Inc (STXS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7222 seconds.